RU2016102339A - Лечение остеоартрита - Google Patents
Лечение остеоартрита Download PDFInfo
- Publication number
- RU2016102339A RU2016102339A RU2016102339A RU2016102339A RU2016102339A RU 2016102339 A RU2016102339 A RU 2016102339A RU 2016102339 A RU2016102339 A RU 2016102339A RU 2016102339 A RU2016102339 A RU 2016102339A RU 2016102339 A RU2016102339 A RU 2016102339A
- Authority
- RU
- Russia
- Prior art keywords
- subject
- antagonist
- csf
- osteoarthritis treatment
- antibody specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Virology (AREA)
- Polarising Elements (AREA)
- Glass Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (5)
1. Способ лечения остеоартрита у субъекта, включающий стадию введения субъекту эффективного количества антагониста гранулоцитарно-макрофагального колониестимулирующего фактора (GM-CSF).
2. Способ по п. 1, где указанный субъект представляет собой человека.
3. Способ по п. 1, где указанный субъект представляет собой мышь.
4. Способ по п. 1, где указанный антагонист представляет собой антитело, специфичное в отношении GM-CSF.
5. Способ по п. 1, где указанный антагонист представляет собой антитело, специфичное в отношении рецептора GM-CSF.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13967908P | 2008-12-22 | 2008-12-22 | |
| US61/139,679 | 2008-12-22 | ||
| US16448609P | 2009-03-30 | 2009-03-30 | |
| US61/164,486 | 2009-03-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011127334/15A Division RU2011127334A (ru) | 2008-12-22 | 2009-12-21 | Лечение остеоартрита |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016102339A true RU2016102339A (ru) | 2018-11-21 |
| RU2016102339A3 RU2016102339A3 (ru) | 2019-07-29 |
| RU2712273C2 RU2712273C2 (ru) | 2020-01-28 |
Family
ID=42286786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011127334/15A RU2011127334A (ru) | 2008-12-22 | 2009-12-21 | Лечение остеоартрита |
| RU2016102339A RU2712273C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение остеоартрита |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011127334/15A RU2011127334A (ru) | 2008-12-22 | 2009-12-21 | Лечение остеоартрита |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9243061B2 (ru) |
| EP (2) | EP3056217B1 (ru) |
| JP (3) | JP5727379B2 (ru) |
| KR (2) | KR101799264B1 (ru) |
| CN (2) | CN106397591A (ru) |
| AU (1) | AU2009329814B2 (ru) |
| BR (1) | BRPI0918356B1 (ru) |
| CA (1) | CA2746827C (ru) |
| CY (1) | CY1117698T1 (ru) |
| DK (1) | DK2376121T4 (ru) |
| ES (2) | ES2886063T3 (ru) |
| HK (1) | HK1226938A1 (ru) |
| HR (1) | HRP20160577T4 (ru) |
| HU (1) | HUE028615T2 (ru) |
| PL (1) | PL2376121T5 (ru) |
| RU (2) | RU2011127334A (ru) |
| SI (2) | SI2376121T1 (ru) |
| SM (1) | SMT201600156B (ru) |
| WO (1) | WO2010071924A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2376121T5 (pl) | 2008-12-22 | 2021-09-27 | The University Of Melbourne | Leczenie zapalenia kości i stawów |
| CN108014335A (zh) | 2008-12-22 | 2018-05-11 | 墨尔本大学 | 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途 |
| IN2015KN00657A (ru) | 2012-09-20 | 2015-07-17 | Morphosys Ag | |
| DE102013222200A1 (de) * | 2013-10-31 | 2015-08-27 | Osram Opto Semiconductors Gmbh | Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements |
| EP3668500A4 (en) * | 2017-08-14 | 2021-04-28 | Zynerba Pharmaceuticals, Inc. | METHODS OF TREATING ARTHROSIS USING TRANSDERMAL CANNABIDIOL GEL |
| WO2020104833A1 (en) * | 2018-11-19 | 2020-05-28 | 4P-Pharma | Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production |
| CN110075304B (zh) * | 2019-05-29 | 2020-02-11 | 四川大学华西医院 | 一种治疗骨关节炎的药物组合物及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0482086A1 (en) | 1989-07-14 | 1992-04-29 | Schering Corporation | Antagonists of gm-csf derived from the carboxyl terminus |
| WO1991002063A1 (en) | 1989-08-11 | 1991-02-21 | Amrad Corporation Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| CA2149881A1 (en) | 1992-11-19 | 1994-05-26 | Paul T. Jubinsky | Antibodies for gm-csf receptor and uses thereof |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| WO2003035048A2 (en) * | 2001-10-26 | 2003-05-01 | Novartis Ag | Methods for the treatment of osteoarthritis and compositions thereof |
| ATE509032T1 (de) | 2002-02-13 | 2011-05-15 | Ludwig Inst For Cancer Res Ltd | Chimerizierte gm-csf antikörper |
| US20040241755A1 (en) * | 2003-06-02 | 2004-12-02 | Pfizer Inc. | Human cell assay to determine effect of sample compounds on Col2 enhancer expression |
| JP2008505054A (ja) | 2004-02-11 | 2008-02-21 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｉｌ−６アンタゴニストで骨関節炎を治療する方法 |
| CN1960758B (zh) * | 2004-03-31 | 2014-10-22 | 中外制药株式会社 | 关节炎的治疗剂或预防剂 |
| DK1593690T3 (da) | 2004-05-05 | 2009-11-09 | Micromet Ag | Fremstilling af ScFv-antistoffragmenter |
| CA2575439A1 (en) | 2004-08-18 | 2006-03-02 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Biomarkers for osteoarthritis |
| US20060040258A1 (en) | 2004-08-23 | 2006-02-23 | Huiyan Guo | Water-soluble conjugates and methods of preparation |
| BRPI0608281B8 (pt) | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| HRP20220755T3 (hr) * | 2005-05-18 | 2022-09-02 | Morphosys Ag | Anti-gm-csf antitijela i njihova uporaba |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| BRPI0619224A2 (pt) * | 2005-12-01 | 2017-06-20 | Domantis Ltd | monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória |
| LT1981909T (lt) * | 2006-02-08 | 2017-01-10 | Morphotek, Inc. | Antigeniniai gm-csf peptidai ir gm-csf antikūnai |
| CN101443360B (zh) * | 2006-03-27 | 2013-11-27 | 医学免疫有限公司 | Gm-csf受体结合元件 |
| US7741273B2 (en) * | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| ES2432173T3 (es) * | 2006-11-21 | 2013-12-02 | Kalobios Pharmaceuticals, Inc. | Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF |
| WO2008080134A2 (en) * | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| JP2010527939A (ja) * | 2007-05-23 | 2010-08-19 | シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド | 中和抗体 |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| US20090163440A1 (en) * | 2007-09-26 | 2009-06-25 | Waddell David D | Ion-Channel Regulator Compositions and Methods of Using Same |
| WO2009062238A1 (en) | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| TWI434854B (zh) * | 2007-11-13 | 2014-04-21 | Evec Inc | 結合ｈＧＭ－ＣＳＦ的單株抗體以及包含其之醫學組成物 |
| CN102282173A (zh) | 2008-03-24 | 2011-12-14 | 艾博特生物技术有限公司 | 用于治疗骨丢失的方法和组合物 |
| KR101824512B1 (ko) * | 2008-04-28 | 2018-02-02 | 휴머니건, 아이엔씨. | 과립구-대식세포 콜로니 자극 인자에 대한 항체 |
| PL2376121T5 (pl) | 2008-12-22 | 2021-09-27 | The University Of Melbourne | Leczenie zapalenia kości i stawów |
| CN108014335A (zh) | 2008-12-22 | 2018-05-11 | 墨尔本大学 | 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途 |
| WO2010124163A2 (en) | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
-
2009
- 2009-12-21 PL PL09833924T patent/PL2376121T5/pl unknown
- 2009-12-21 US US13/140,467 patent/US9243061B2/en active Active
- 2009-12-21 JP JP2011541030A patent/JP5727379B2/ja active Active
- 2009-12-21 BR BRPI0918356-6A patent/BRPI0918356B1/pt active IP Right Grant
- 2009-12-21 RU RU2011127334/15A patent/RU2011127334A/ru unknown
- 2009-12-21 KR KR1020117017015A patent/KR101799264B1/ko active IP Right Grant
- 2009-12-21 SI SI200931446A patent/SI2376121T1/sl unknown
- 2009-12-21 KR KR1020177032850A patent/KR101898982B1/ko active IP Right Grant
- 2009-12-21 ES ES15194091T patent/ES2886063T3/es active Active
- 2009-12-21 WO PCT/AU2009/001672 patent/WO2010071924A1/en active Application Filing
- 2009-12-21 HU HUE09833924A patent/HUE028615T2/en unknown
- 2009-12-21 CN CN201610822096.9A patent/CN106397591A/zh active Pending
- 2009-12-21 CN CN2009801516359A patent/CN102271705A/zh active Pending
- 2009-12-21 CA CA2746827A patent/CA2746827C/en active Active
- 2009-12-21 ES ES09833924T patent/ES2572368T5/es active Active
- 2009-12-21 SI SI200931446T patent/SI2376121T2/sl unknown
- 2009-12-21 RU RU2016102339A patent/RU2712273C2/ru active
- 2009-12-21 EP EP15194091.3A patent/EP3056217B1/en active Active
- 2009-12-21 DK DK09833924.5T patent/DK2376121T4/da active
- 2009-12-21 EP EP09833924.5A patent/EP2376121B2/en active Active
- 2009-12-21 AU AU2009329814A patent/AU2009329814B2/en active Active
-
2015
- 2015-02-20 JP JP2015031198A patent/JP2015143233A/ja active Pending
- 2015-12-18 US US14/975,024 patent/US20160185868A1/en not_active Abandoned
-
2016
- 2016-05-18 CY CY20161100433T patent/CY1117698T1/el unknown
- 2016-05-30 HR HRP20160577TT patent/HRP20160577T4/hr unknown
- 2016-06-01 SM SM201600156T patent/SMT201600156B/it unknown
- 2016-12-06 HK HK16113893A patent/HK1226938A1/zh unknown
-
2017
- 2017-06-12 JP JP2017114806A patent/JP6458086B2/ja active Active
- 2017-11-13 US US15/811,279 patent/US20180066062A1/en not_active Abandoned
-
2020
- 2020-03-31 US US16/836,464 patent/US20200247895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016102339A (ru) | Лечение остеоартрита | |
| RU2016102346A (ru) | Лечение боли | |
| SI1874819T1 (sl) | Protitelesni nevtralizatorji humanega faktorja stimulacije kolonij granulocitov makrofagov | |
| CY2014006I1 (el) | Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf | |
| EA201101571A1 (ru) | Композиции и способы для усиления мышечного роста | |
| BRPI1007877A2 (pt) | "inibidores de dpp-iv para o tratamento de diabetes em pacientes pediátricos" | |
| EA201290189A1 (ru) | Человеческие нейтрализующие антитела анти-ngf в качестве селективных ингибиторов метаболических путей фактора роста нервов | |
| DK2327423T5 (da) | Humane antistoffer mod humant interleukin-22 (IL-22) | |
| JP2012512814A5 (ru) | ||
| SI3135672T1 (sl) | Sestavki in postopki za zdravljenje motenj, bolečin in drugih bolezni povezanih z uporabo alkohola | |
| PL2262778T3 (pl) | Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CXCR1 i p40 | |
| BR112012026707A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado | |
| BRPI0911902A2 (pt) | anticorpos para fator estimulador de colônia granulocítica-macrofágica | |
| SI2771329T1 (sl) | Nove disubstituirane 3,4-diamino-3-ciklobuten-1,2-dion-spojine za uporabo pri tretiranju kemokin mediiranih bolezni | |
| JP2012512815A5 (ru) | ||
| FR2953520B1 (fr) | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique | |
| FR2952934B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| UA107201C2 (uk) | 4-[етил(диметил)амоній]бутаноат та його застосування в лікуванні серцево-судинної хвороби | |
| DK2341061T3 (da) | Ny fremgangsmåde til fremstilling af G-CSF (granulocytkoloni-stimulerende faktor) | |
| BRPI0811649A2 (pt) | Método para produzir fator de von willebrand maduro a partir de pró-peptídeo de fator de von willebrand, uso de um fator de von willebrand maduro, e, método para tratar doença de von willebrand em um mamífero | |
| de Santé | Éducation thérapeutique du patient: Comment la proposer et la réaliser | |
| IL213440A0 (en) | Use of racemates of pinocembrin in preparing medicaments for treating stroke | |
| SMT201600416B (it) | Uso di sali di 3-carbossi-n-etil-n,n-dimetilpropan-1-amminio nel trattamento di malattie cardiovascolari | |
| EA201190064A1 (ru) | Соединения этанамина и их применение для лечения депрессии | |
| FR2953713B1 (fr) | Composition cosmetique capillaire, detergente et lissante, et procede de traitement cosmetique mettant en oeuvre ladite composition |